Medical Devices and Diagnostics  Segment Sales Sales by Major Franchise  (in billions of dollars) the most significant need. In Oncology, Velcade* (bortezomib), for multiple myeloma,  grew  16  percent operationally while eclipsing $ 1  billion in sales  outside the U.S. for the first time.  In addition, we continue to pursue line extensions. We submitted applications for several major line extensions,  among them  REMICADE ®  and  SIMPONI ® , which continue to build the strength of our Immunology franchise. Over the next three years, we expect to file compounds to  address critical medical needs, including Alzheimer’s disease and  diabetes, conditions growing in prevalence as the population  ages. With five compounds currently in registration and several  more planned in the coming years, our portfolio ranks among the  leaders in the industry. Our pipeline meets unmet needs and  features many true innovations designed to change the treatment  paradigm for patients. The Medical Devices and Diagnostics (MD&D) franchises  comprise the world’s largest medical technology business, with  sales of $ 24 . 6  billion, an increase of approximately  3  percent  operationally. Despite the economic slowdown, which led to a  decline in surgical procedures and pricing pressures across the  business, we achieved growth in six of our seven franchises, as  well as in all regions. Our MD&D businesses advanced a very strong pipeline,  completed and integrated several acquisitions, and aggressively  expanded into emerging markets. The segment maintained or  improved market share in the majority of its largest product  platforms, despite intense competition. For example, the Ethicon franchise grew  8  percent  operationally, based on its strong suite of surgical products, as  well as recent acquisitions in new markets like aesthetics and ear,  nose and throat surgery. The Ethicon Endo-Surgery franchise  grew  5  percent operationally. Double-digit growth in its advanced  sterilization products and energy products were major  contributors. Our Vision Care franchise had operational sales  growth of  4  percent based on its core  ACUVUE ®  Brand Contact  Lens and the continued launch of  1 - DAY ACUVUE ®  TruEye ™ Contact Lenses into new markets. The Ortho Clinical Diagnostics  franchise grew  4  percent operationally with the continued growth  of the  VITROS ® 3600  and  5600  analyzers. The DePuy franchise increased operational sales by  3  percent  based on the strength of its orthopaedic reconstruction, sports  medicine and neurological businesses. Diabetes Care increased  operational sales by  2  percent with the introduction of a number  of new OneTouch $^{®}$ products around the world. Meanwhile, sales in the Cordis franchise continued to decline due to competi- tion in drug-eluting stents. This was partially offset by the strong  growth of electrophysiology products in the Biosense Webster  business, which grew nearly  20  percent operationally for the year.  Consumer sales were $ 14 . 6  billion, a decline of approximately  9  percent operationally. Sales were impacted by McNeil recalls, as  well as the general economic slowdown and greater consumer  sensitivity to spending, reflected in a broad move towards store  JOHNSON & JOHNSON 2010 ANNUAL REPORT 4 P har m 2010 Sales: $22.4 billion Sales Change Total: (0.6%) Operational*: (1.0%) LEVAQUIN®/ FLOXIN® $1.4 (12.5%) PROCRIT®/ EPREX® $1.9 (13.9%) OTHER $9.1 6.6% CONCERTA® $1.3 (0.5%) REMICADE® $4.6 7.1%  RISPERDAL® CONSTA® $1.5 5.3% TOPAMAX® $0.5 (53.3%) VELCADE® $1.1 15.8% ACIPHEX®/  PARIET® $1.0 (8.2%) * Velcade is a trademark of Millennium Pharmaceuticals, Inc. CONSUMER Consumer Segment Sales Sales by Major Franchise  (in billions of dollars) 2010 Sales: $14.6 billion Sales Change Total: (7.7%) Operational*: (8.9%)  BABY CARE $2.2 4.4% SKIN CARE $3.5 (0.4%)  WOUND  CARE/ OTHER $1.0 (10.4%) OTC  PHARMACEUTICALS  & NUTRITIONALS $4.6 (19.2%) ORAL CARE $1.5 (2.7%) C onsumer WOMEN’S  HEALTH $1.8  (2.7%) Pharmaceutical Segment Sales Sales by Major Product  (in billions of dollars) MEDICAL DEVICES AND DIAGNOSTICS 2010  Sales:  $24.6  billion Sales Change Total:  4.4% Operational*:  3.4% MD&D  DEPUY® $5.6 4.0% ETHICON ENDO-SURGERY® $4.8 5.9% DIABETES  CARE $2.5 1.2% ORTHO-CLINICAL DIAGNOSTICS® $2.0 4.6% VISION CARE $2.7 6.9% CORDIS® $2.5 (4.7%) ETHICON® $4.5 9.2% *Operational excludes the impact of currency